Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Chronic urticaria and angioedema

Paediatrics and child health · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Airway swelling or systemic compromise

Tongue or throat swelling, stridor, wheeze, hypoxia, hypotension or collapse requires immediate anaphylaxis assessment; isolated skin wheals alone are not anaphylaxis.

Action: Use ABCDE and give intramuscular adrenaline promptly when airway, breathing or circulation compromise suggests anaphylaxis, while obtaining senior airway support and distinguishing recurrent bradykinin-mediated angioedema.

Synopsis

Recognise chronic spontaneous and inducible urticaria, separate mast-cell angioedema from bradykinin disease and vasculitis, investigate selectively and escalate non-sedating antihistamine treatment without unnecessary food restriction.

  • Urticaria produces itchy raised wheals that migrate and usually disappear from each site within 24 hours; chronic means recurring on most days for more than six weeks.
  • Angioedema affects deeper eyelid, lip, hand, foot or genital tissue and may last up to 72 hours; airway symptoms require an anaphylaxis pathway.
  • Chronic spontaneous urticaria in children is rarely driven by food allergy, so broad IgE panels and exclusion diets are usually harmful.
  • Ask for photographs and lesion duration, triggers, NSAIDs, infection, physical stimuli and systemic symptoms; provocation testing confirms suspected inducible forms.
  • Do not routinely order large autoimmune, infectious or allergy screens in an otherwise well child with classic transient wheals.
  • Use a daily second-generation non-sedating H1 antihistamine rather than as-needed first-generation sedatives; check adherence before declaring failure.
  • Under specialist guidance, increase a second-generation antihistamine up to fourfold the licensed standard dose when ordinary dosing fails, with age-appropriate selection and monitoring.
  • Omalizumab is a specialist add-on for severe chronic spontaneous urticaria from age 12 when high-dose H1 treatment remains inadequate; ciclosporin is a later selected option.
  • Systemic corticosteroids are not maintenance therapy; a very short rescue course is reserved for exceptional severe flares under a clear plan.
  • Recurrent isolated angioedema without wheals needs C4 and C1-inhibitor assessment and a separate hereditary-angioedema emergency plan.

Key red flags

Angioedema with tongue or laryngeal symptoms, breathing difficulty or circulatory change is an emergency regardless of whether urticaria is visible.

Individual lesions that remain fixed beyond 24 hours, hurt or burn and leave bruising or pigmentation suggest urticarial vasculitis and need specialist investigation.

Recurrent non-itchy angioedema without wheals, especially with abdominal pain or family history, suggests hereditary C1-inhibitor deficiency.

Fever, bone pain, weight loss, lymphadenopathy, hepatosplenomegaly or persistently abnormal inflammatory markers broadens systemic inflammatory, infectious and malignant differentials.

Food is rarely the cause of near-daily wheals for more than six weeks; temporal claims need reproducible immediate exposure evidence before restriction.

Sedation, school impairment or paradoxical excitation from first-generation antihistamines is avoidable and should prompt a second-generation regimen.

Investigation priorities

01
First-line photographs and lesion timelineFirst stepFirst line

Confirm evanescence, distinguish wheals from fixed inflammation and document angioedema distribution.

Management branches

TriageSeparate skin disease from emergency

Wheals or swelling appear acutely or recur.

  1. Assess airway, breathing and circulation and give adrenaline if anaphylaxis physiology is present.
  2. Confirm lesion duration, itch, bruising and whether angioedema occurs with or without wheals.
  3. Escalate fixed vasculitic lesions and isolated laryngeal or abdominal swelling through the correct pathway.

Key medicines

CetirizineUse an age-licensed daily dose: commonly 2.5 mg twice daily from 2–5 years, 5 mg twice daily from 6–11 years and 10 mg once daily from 12 years; specialist CSU protocols may increase up to fourfold when standard dosing fails.Renal impairment requires dose review and some children still become drowsy; avoid stacking multiple antihistamines or unplanned up-dosing without documenting age, response and safety.
OmalizumabFor chronic spontaneous urticaria from age 12 with inadequate response to high-dose H1 antihistamine, give 300 mg subcutaneously every 4 weeks through specialist care and assess response at defined intervals.Administer with anaphylaxis capability, record batch and monitor injection reactions; reassess benefit before prolonged treatment and do not use it to treat acute anaphylaxis.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • BSACI-endorsed 2026 International Urticaria GuidelineCurrent definition, selective investigation, antihistamine escalation, omalizumab and angioedema differentiation.
  • NHS Hives OverviewRecognition, urgent swelling features and general treatment.
  • NICE Omalizumab Technology AppraisalOmalizumab commissioning for severe chronic spontaneous urticaria.
  • Resuscitation Council UK AnaphylaxisEmergency differentiation and adrenaline treatment for systemic compromise.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom